Mauricio Sainz-Barriga
Overview
Explore the profile of Mauricio Sainz-Barriga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
211
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vanlerberghe B, van Malenstein H, Sainz-Barriga M, Jochmans I, Cassiman D, Monbaliu D, et al.
Transpl Int
. 2024 Mar;
37:12055.
PMID: 38440132
malignancy (DNM) is the primary cause of mortality after liver transplantation (LT) for alcohol-related liver disease (ALD). However, data on risk factors for DNM development after LT are limited, specifically...
2.
Lerut A, Pirenne J, Sainz-Barriga M, Blondeel J, Maleux G, Monbaliu D
Front Surg
. 2023 Jul;
10:1169556.
PMID: 37440926
Introduction: Hepatic artery pseudoaneurysm (HAPA), a rare vascular complication that can develop after liver transplantation, is associated with a high mortality rate and graft loss. To salvage the liver graft,...
3.
Clarysse M, Wilmer A, Debaveye Y, Laleman W, Devos T, Canovai E, et al.
Pediatr Transplant
. 2021 Jul;
25(8):e14097.
PMID: 34289227
Background: Diffuse splanchnic thrombosis may render standard LTx difficult or even technically impossible. A 19-year-old woman with acute-on-chronic Budd-Chiari syndrome and complete splanchnic thrombosis underwent conventional LTx. Only limited anatomical...
4.
Van Herck J, Verbeek J, van Malenstein H, Laleman W, Cassiman D, Verslype C, et al.
Transplant Proc
. 2021 May;
53(5):1674-1681.
PMID: 34016462
Background: The increasing rate of liver transplantation (LT) for nonalcoholic fatty liver disease (NAFLD) raises concerns on cardiovascular morbidity and mortality after LT in these patients. Methods: We collected variables...
5.
Van den Eynde J, Achtergaele J, Fieuws S, Jochmans I, Sainz-Barriga M, Monbaliu D, et al.
Transpl Int
. 2020 Dec;
34(2):327-338.
PMID: 33280170
The effect of preservation solutions on outcomes has been subject of many debates but the relative benefits of the various solutions remain unclear. We retrospectively compared short-term outcomes of 885...
6.
Gilbo N, Fieuws S, Meurisse N, Nevens F, van der Merwe S, Laleman W, et al.
Transplantation
. 2020 Oct;
105(5):1030-1038.
PMID: 33052640
Background: Donor hepatectomy and liver implantation time reduce long-term graft and patient survival after liver transplantation. It is not known whether these surgical times influence early outcomes after liver transplantation....
7.
De Beule J, Fieuws S, Monbaliu D, Naesens M, Sainz-Barriga M, Sprangers B, et al.
Am J Transplant
. 2020 Sep;
21(2):830-837.
PMID: 32888364
Institut Georges Lopez-1 (IGL-1) solution is increasingly used for kidney preservation, although little information on outcomes is available. Outcomes of all deceased donor kidneys preserved by IGL-1, University of Wisconsin...
8.
Canovai E, Cassiman C, Ceulemans L, Demaerel P, Sainz-Barriga M, Jochmans I, et al.
Transplant Direct
. 2020 Feb;
6(1):e516.
PMID: 32047844
No abstract available.
9.
Gilbo N, Jochmans I, Jacobs-Tulleneers-Thevissen D, Wolthuis A, Sainz-Barriga M, Pirenne J, et al.
JAMA
. 2019 Jul;
322(1):78-80.
PMID: 31265090
No abstract available.
10.
Troisi R, Vanlander A, Giglio M, van Limmen J, Scudeller L, Heyse B, et al.
Ann Surg
. 2019 May;
269(6):1025-1033.
PMID: 31082898
Objective: To investigate the safety and efficacy of somatostatin as liver inflow modulator in patients with end-stage liver disease (ESLD) and clinically significant portal hypertension (CSPH) undergoing liver transplantation (LT)...